Nantahala Capital Management LLC 13D and 13G filings for Evoke Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2025-02-03 4:47 pm Purchase |
2025-02-03 | 13D | Evoke Pharma, Inc. EVOK |
Nantahala Capital Management LLC | 254,639 15.990% |
7![]() (+0.00%) |
Filing |
2024-11-06 4:31 pm Purchase |
2024-11-06 | 13D | Evoke Pharma, Inc. EVOK |
Nantahala Capital Management LLC | 254,632 15.990% |
169,946![]() (+200.68%) |
Filing |
2024-10-01 4:53 pm Unchanged |
2024-09-27 | 13D | Evoke Pharma, Inc. EVOK |
Nantahala Capital Management LLC | 84,686 10.000% |
0 (Unchanged) |
Filing |
2024-09-20 7:28 pm Purchase |
2024-09-20 | 13D | Evoke Pharma, Inc. EVOK |
Nantahala Capital Management LLC | 84,686 10.000% |
84,686![]() (New Position) |
Filing |